Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies.

Deng J, Gu S, Shao H, Dong H, Zou D, Shi L

Journal of medical economics20 Aug 2015Cited by 19 (Europe PMC)

PMID26134916DOI10.3111/13696998.2015.1067622PepBankPUB-26134916

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
The model predicted greater quality-adjusted survival with exenatide plus oral agents than insulin glargine plus oral agents in Chinese diabetes patients.
In plain wordsComputer modelling predicted greater quality-adjusted survival with exenatide than insulin glargine, each with oral agents.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseQuality-adjusted life years
Study
n: not reported in source
Cardiff model
Comparator
Insulin glargine plus oral anti-diabetic agents
Outcome group
Cost-effectiveness · Whole body
Measurements
QALY gain
1.88 QALYs
versus insulin glargine plus OAD
Source sentences
Summary
Compared with insulin glargine plus OAD treatments, patients on exenatide BID plus OAD gained 1.88 QALYs, at an incremental cost saving of Chinese Renminbi (RMB) 114,593 (i.e., cost saving of RMB 61078/QALY).
2 context sentences(design, population, supporting numbers)
Summary · context
The Cardiff model was populated with data synthesized from three head-to-head randomized clinical trials of up to 30 weeks in China comparing exenatide BID vs insulin glargine as add-on therapies to oral therapies in the Chinese population.
Summary · context
Cost and QALYs were estimated with a time horizon of 40 years at a discount rate of 3% from a societal perspective.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2613491601
02Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
The model predicted lower costs with exenatide plus oral agents than insulin glargine plus oral agents in Chinese diabetes patients.
In plain wordsComputer modelling predicted lower costs with exenatide than insulin glargine, each with oral agents.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseIncremental cost savings
Study
n: not reported in source
Cardiff model
Comparator
Insulin glargine plus oral anti-diabetic agents
Outcome group
Cost-effectiveness · Whole body
Measurements
Cost saving
114,593 RMB
versus insulin glargine plus OAD
Cost saving per QALY
61,078 RMB/QALY
versus insulin glargine plus OAD
Source sentences
Summary
Compared with insulin glargine plus OAD treatments, patients on exenatide BID plus OAD gained 1.88 QALYs, at an incremental cost saving of Chinese Renminbi (RMB) 114,593 (i.e., cost saving of RMB 61078/QALY).
2 context sentences(design, population, supporting numbers)
Summary · context
The Cardiff model was populated with data synthesized from three head-to-head randomized clinical trials of up to 30 weeks in China comparing exenatide BID vs insulin glargine as add-on therapies to oral therapies in the Chinese population.
Summary · context
Cost and QALYs were estimated with a time horizon of 40 years at a discount rate of 3% from a societal perspective.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2613491602
03Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
In the exenatide cost-effectiveness model, sensitivity analyses supported robust results.
In plain wordsComputer modelling found robust cost-effectiveness results for exenatide versus insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableCost-effectiveness sensitivity
Study
n: not reported in source
Cardiff model
Comparator
Insulin glargine plus oral anti-diabetic agents
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The cost-effectiveness results were robust to various sensitivity analyses including probabilistic sensitivity analysis.
2 context sentences(design, population, supporting numbers)
Summary · context
The Cardiff model was populated with data synthesized from three head-to-head randomized clinical trials of up to 30 weeks in China comparing exenatide BID vs insulin glargine as add-on therapies to oral therapies in the Chinese population.
Summary · context
Cost and QALYs were estimated with a time horizon of 40 years at a discount rate of 3% from a societal perspective.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2613491603
04Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
In the exenatide model, baseline HbA1c, health utility decrement and baseline BMI most affected the incremental cost-effectiveness ratio.
In plain wordsComputer modelling identified baseline blood sugar, health utilities and body mass as major cost-effectiveness drivers.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableCost-effectiveness drivers
Study
n: not reported in source
Cardiff model
Comparator
Insulin glargine plus oral anti-diabetic agents
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The variables with the most impact on incremental cost-effectiveness ratio included HbA1c level at baseline, health utilities decrement, and BMI at baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
The Cardiff model was populated with data synthesized from three head-to-head randomized clinical trials of up to 30 weeks in China comparing exenatide BID vs insulin glargine as add-on therapies to oral therapies in the Chinese population.
Summary · context
Cost and QALYs were estimated with a time horizon of 40 years at a discount rate of 3% from a societal perspective.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2613491604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.